The Com-Cov study, announced earlier this year, is the first trial in the world to evaluate the effects of using different COVID-19 vaccines for the first and second dose within a two-dose vaccination regimen.
It is designed to monitor the impact of the different dosing regimens on immune responses. It is being run by the National Immunisation Schedule Evaluation Consortium (NISEC) across eight National Institute for Health Research (NIHR) supported sites.
